1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
/Steris%20Plc%20logo%20and%20chart-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
STERIS has underperformed the Nasdaq over the past year, but analysts are cautiously optimistic about the stock’s prospects.
Bio-Techne, Bruker, DexCom, STERIS, and Teleflex Shares Plummet, What You Need To Know
/Dexcom%20Inc%20logo%20on%20sign-by%20Michael%20Vi%20via%20Shutterstock.jpg)
DexCom has underperformed the Nasdaq Composite over the past year, yet analysts remain highly optimistic about the stock’s future.
/Steris%20Plc%20site%20and%20phone-by%20T_Schneider%20via%20Shutterstock.jpg)
Despite STERIS' outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
The 5 Most Interesting Analyst Questions From STERIS’s Q4 Earnings Call
STERIS (NYSE:STE) Beats Q4 CY2025 Sales Expectations
Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53 Fiscal...